| Title |
Acetylcholinesterase inhibitors for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2012
|
| DOI | 10.1002/14651858.cd007967.pub2 |
| Pubmed ID | |
| Authors |
Jasvinder Singh, Kamalpreet Kour, Mahesh B Jayaram |
| Abstract |
Antipsychotic medication remains the mainstay of treatment for schizophrenia and has been in use for a long time. As evidenced by ongoing research and partial effectiveness of the antipsychotics on cognitive and negative symptoms, the search is on for drugs that may improve these domains of functioning for someone suffering from schizophrenia. Acetylcholinesterase inhibitors have long been in use for treating cognitive symptoms of dementia. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 20% |
| India | 1 | 10% |
| United States | 1 | 10% |
| Unknown | 6 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 60% |
| Practitioners (doctors, other healthcare professionals) | 4 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 240 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 239 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 44 | 18% |
| Researcher | 29 | 12% |
| Student > Bachelor | 26 | 11% |
| Student > Ph. D. Student | 23 | 10% |
| Student > Doctoral Student | 15 | 6% |
| Other | 34 | 14% |
| Unknown | 69 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 68 | 28% |
| Psychology | 32 | 13% |
| Nursing and Health Professions | 16 | 7% |
| Neuroscience | 9 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 3% |
| Other | 28 | 12% |
| Unknown | 79 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 August 2022.
All research outputs
#4,145,577
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#6,429
of 11,499 outputs
Outputs of similar age
#32,871
of 251,889 outputs
Outputs of similar age from Cochrane database of systematic reviews
#92
of 227 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 227 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.